Table 2 Univariate and multivariate COX regression analyses for the whole cohort before PSM.
Univariate Cox Analysis | Multivariate Cox Analysis | |||
|---|---|---|---|---|
Characteristics | HR (95% CI) | P value | HR (95% CI) | P value |
Age | 0.437 | |||
≤45 | Reference | |||
>45 | 1.1 (0.87–1.38) | |||
Sex | 0.643 | |||
Male | Reference | |||
Female | 0.94 (0.71–1.23) | |||
T Stage | 0.783 | |||
T1–2 | Reference | |||
T3–4 | 0.95 (0.65–1.39) | |||
N Stage | 0.003 | 0.008 | ||
N0–1 | Reference | Reference | ||
N2–3 | 1.78 (1.22–2.58) | 1.67(1.14–2.44) | ||
Overall stage | 0.020 | 0.03 | ||
III | Reference | Reference | ||
IVA | 1.33 (1.05–1.7) | 1.31 (1.03–1.67) | ||
ECOG PS | 0.261 | |||
0–1 | Reference | |||
>1 | 1.32 (0.81–2.16) | |||
Induction chemotherapy regimen | ||||
GP | Reference | |||
TPF | 0.91 (0.66–1.24) | 0.535 | ||
TP | 1.17 (0.83–1.66) | 0.373 | ||
TPC | 1.05 (0.68–1.63) | 0.816 | ||
Other or more | 1.61 (0.97–2.68) | 0.065 | ||
Induction chemotherapy cycle | 0.949 | |||
2 Cycles | Reference | |||
3 Cycles | 0.99 (0.79–1.25) | |||
Pre-treatment EBV DNA level | <0.001 | 0.065 | ||
<4000 copies/mL | Reference | Reference | ||
≥4000 copies/mL | 1.62 (1.28–2.04) | 1.25 (0.99–1.59) | ||
EBV DNA level after first cycle | <0.001 | 0.014 | ||
Undetectable | Reference | Reference | ||
Detectable | 2 (1.56–2.57) | 1.41 (1.07–1.87) | ||
EBV DNA level after IC | <0.001 | < 0.001 | ||
Undetectable | Reference | Reference | ||
Detectable | 2.23 (1.76–2.81) | 1.77 (1.36–2.32) | ||
EBV DNA level after CCRT | <0.001 | < 0.001 | ||
Undetectable | Reference | Reference | ||
Detectable | 3.63 (2.5–5.26) | 2.50 (1.69–3.70) | ||
Concurrent chemotherapy cycles | <0.001 | < 0.001 | ||
2 Cycles | Reference | Reference | ||
3 Cycles | 0.61 (0.47–0.8) | 0.6 (0.46–0.79) | ||
Adjuvant therapy | 0.834 | |||
No | Reference | |||
Yes | 0.96 (0.64–1.43) | |||
